Loading
A phase 1/2 trial of Atezolizumab, Gemcitabine and Trifluridine/tipiracil in anal cancer and pancreatic ductal adenocarcinoma, run by Oncolytics Biotech, active and no longer recruiting.
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab is a phase 1/2 interventional study registered as NCT07280377 by Oncolytics Biotech, with 122 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2027-07-30. Interventions recorded: Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil and mFOLFIRINOX Treatment Regimen.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.